Venus Medtech (Hangzhou), Inc. Class H 2500

HKEX · Hong Kong SAR China · Health Technology

HKD 1.20-0.03 (-2.45%)

Market closed· Oct 2, 2026, 7:54 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Venus Medtech (Hangzhou), Inc. Class H 2500

HKEX · Hong Kong SAR China · Health Technology

HKD 1.20-0.03 (-2.45%)

Market closed· Oct 2, 2026, 7:54 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-45.43% · 6MFull-screen chart

Open HKD 1.24High HKD 1.24Low HKD 1.17Close HKD 1.20Volume 252.50K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: HKD 1.23
Day range: HKD 1.18 – HKD 1.24
52-week range: HKD 0.9400 – HKD 3.86
Volume: 252.50K
Market cap: HKD 540.24M
Next earnings date: 2027-04-01
Avg. volume (1Y): 1.40M

Performance

1 week

+0.42%

1 month

+6.22%

3 months

-26.69%

6 months

-45.18%

Year to date

-51.42%

1 year

-64.85%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Medical Specialties
Country: Hong Kong SAR China
Exchange: HKEX
Shares outstanding: 437.90M
Employees: 560
ISIN: CNE100003PJ8
Beta: 0.88

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceOct 25, 2025

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve's Transcatheter Tricuspid Valve Replacement (TTVR) system, the company's flagship solution for treating tricuspid regurgitat

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.